▲ +38.58% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for GW Pharmaceuticals in the last 3 months. The average price target is $188.09, with a high forecast of $275.00 and a low forecast of $128.00. The average price target represents a 38.58% upside from the last price of $135.73.
The current consensus among 12 contributing investment analysts is to buy stock in GW Pharmaceuticals. This Buy consensus rating has held steady for over two years.
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, Dravet syndrome, and Lennox-Gastaut syndrome, as well as in phase III clinical trials for the treatment of tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of for schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.